Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop M. Kantarjian, Elias Jabbour, Alessandra Ferrajoli et al.|The Lancet Oncology|2018Cited by 242
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaElias Jabbour, Hagop M. Kantarjian, Farhad Ravandi et al.|JAMA Oncology|2017Cited by 156
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Hagop M. Kantarjian, Nicholas J. Short et al.|The Lancet Haematology|2023Cited by 110
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvageElias Jabbour, Hagop M. Kantarjian, Koji Sasaki et al.|Cancer|2018Cited by 110
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemiaElias Jabbour, Hagop M. Kantarjian, Koji Sasaki et al.|Cancer|2021Cited by 38